ARS Pharmaceuticals, Inc (SPRY) — Strategic Asset Allocation Index
ARS Pharmaceuticals, Inc (SPRY) has a Strategic Asset Allocation Index of 0.2% as of June 2023. Strategic assets (PP&E of $594.00K plus long-term investments of $-) total $594.00K, measured against net assets of $248.55 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See SPRY equity to assets ratio to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
ARS Pharmaceuticals, Inc Strategic Asset Allocation Index (2022–2022)
This chart shows how ARS Pharmaceuticals, Inc's Strategic Asset Allocation Index has evolved across 1 annual periods from 2022 to 2022. As of June 2023, the index stands at 0.2%, representing strategic assets of $594.00K against net assets of $248.55 Million USD. For live market cap and overall valuation, see ARS Pharmaceuticals, Inc market cap and net worth.
Annual Strategic Asset Allocation Index for ARS Pharmaceuticals, Inc (2022–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for ARS Pharmaceuticals, Inc from 2022 to 2022, covering 1 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See ARS Pharmaceuticals, Inc book value and equity for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 0.1% | $329.00K | $329.00K | $- | $272.89 Million | — |